Brief: Apogee To Host Call To Report Interim Results From Phase 1b Trial Of APG777 In Patients With Mild-To-Moderate Asthma

Apogee Therapeutics

05/01/2026 22:13

Jan 5 (Reuters) - Apogee Therapeutics Inc APGE.O:

APOGEE THERAPEUTICS TO HOST CONFERENCE CALL TO REPORT INTERIM RESULTS FROM THE PHASE 1B TRIAL OF APG777 IN PATIENTS WITH MILD-TO-MODERATE ASTHMA AND 2026 ANTICIPATED MILESTONES ON JANUARY 6, 2026

Source text: ID:nGNX4TVHz8

Further company coverage: APGE.O

 ((Reuters.Briefs@thomsonreuters.com;))